当前位置：首页 > 文献互助 > 互助详情

Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia复制

MOMO 2小时前 15 10 已完结

1. 当前求助状态已完结, 请及时下载应助文件

2. 系统将在 2026-02-13 07:58:39 删除文件

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1001/jamacardio.2024.0959复制

文献链接: https://jamanetwork.com/journals/jamacardiology/fullarticle/2817469复制

其他信息:

出版社: American Medical Association (AMA)
作者: Daniel Gaudet; Denes Pall; Gerald F. Watts; Stephen J. Nicholls; Robert S. Rosenson; Karen Modesto; Javier San Martin; Jennifer Hellawell; Christie M. Ballantyne

上一篇：Teachers' flow, emotional well-being, and optimal teaching and learning experiences: An experience sampling study.

下一篇：Parkinson disease therapy: current strategies and future research priorities

互助时间线

2026-02-06 07:59:24 [完结求助]

楼主确认了甜蜜生活应助的文件是正确的, 求助状态变成 已完结

2026-02-06 07:58:39 [上传文件]

甜蜜生活上传了文件(pdf 390.85 KB), 求助状态变成 待确认

2026-02-06 07:58:33 [发起求助]

最新发布的求助

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial 9分钟前
A Pd-labile fluoroquinolone prodrug efficiently prevents biofilm formation on coated surfaces 23分钟前
Design, synthesis, anticancer and antioxidant activities of amide linked 1,4-disubstituted 1,2,3-triazoles 26分钟前
1,2,3-Triazole-based kojic acid analogs as potent tyrosinase inhibitors: Design, synthesis and biological evaluation 31分钟前
Substituted 4-(1H-1,2,3-triazol-1-yl)-tetrafluorobenzoates: Selective synthesis and structure 35分钟前
A Pd-labile fluoroquinolone prodrug efficiently prevents biofilm formation on coated surfaces 38分钟前
Efficient Multicomponent Active Template Synthesis of Catenanes 45分钟前
Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression 49分钟前
Preclinical Development of 3BP-3940, a Fibroblast Activation Protein–Targeted Cyclic Peptide–Based Radiotheranostic for Imaging and Therapy 57分钟前
求该文附件 Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia 1小时前
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia 1小时前
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial 1小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com